Ocuphire Pharma to Speak at Aegis Virtual Conference

Ocuphire Pharma, Inc., a clinical-stage biopharmaceutical company, is advancing the development of innovative treatments targeting retinal and refractive eye disorders. The company recently announced that its CEO, George Magrath, M.D., M.B.A., M.S., will deliver a comprehensive company overview at the upcoming Aegis Virtual Conference scheduled for May 7-9, 2024. Participants will also have the opportunity to engage in one-on-one meetings with the company's management team during the event.

Key information regarding the presentation is as follows:
- Event: Aegis Capital Virtual Conference
- Dates: May 7-9, 2024
- Presentation Title: Ocuphire Pharma, Inc. (OCUP) Company Presentation
- Presenter: George Magrath, M.D., M.B.A., M.S.
- Date: Wednesday, May 8, 2024
- Time: 3:00 – 3:25 pm ET

Ocuphire focuses on developing novel therapies aimed at treating retinal and refractive eye conditions. The company’s leading retinal product candidate, APX3330, is an oral small-molecule inhibitor that targets Ref-1 (reduction oxidation effector factor-1 protein), crucial for treating non-proliferative diabetic retinopathy (NPDR). Ref-1 modulates the transcription factors HIF-1α and NF-κB. By inhibiting Ref-1, the levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines—key elements in ocular angiogenesis and inflammation—are reduced. APX3330 is administered as an oral tablet twice daily for diabetic retinopathy (DR). The Phase 2 study and an End-of-Phase 2 meeting have been concluded, and a special protocol assessment (SPA) was submitted to the U.S. Food and Drug Administration (FDA) in February 2024.

Additionally, Ocuphire has partnered with Viatris, Inc. to develop and commercialize Phentolamine Ophthalmic Solution 0.75% (PS), an adrenergic antagonist formulated to diminish pupil size. In September 2023, the FDA approved PS for treating pharmacologically-induced mydriasis under the RYZUMVI™ brand name. PS is also undergoing Phase 3 clinical trials for treating presbyopia and enhancing visual acuity under low light conditions (mesopic) following keratorefractive surgery.

Moreover, Ocuphire is working on developing APX2009 and APX2014, second-generation analogs of APX3330. These new candidates are being investigated for their potential in treating other retinal diseases, including age-related macular degeneration and geographic atrophy. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!